SEC Form 4 · accession 0001628280-26-047058
Contineum Therapeutics, Inc. · CTNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel S. Lorrain
Officer — Chief Scientific Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 5:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001855175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 30, 2026 | M | 28,826 | $1.01 | A | 168,198 | D | |
| Class A Common StockF2 | Jun 30, 2026 | S | 28,826 | $16.0372 | D | 139,372 | D | |
| Class A Common Stock | Jul 1, 2026 | M | 4,183 | $1.01 | A | 143,555 | D | |
| Class A Common StockF3 | Jul 1, 2026 | S | 5,852 | $15.6667 | D | 137,703 | D | |
| Class A Common StockF4 | Jul 1, 2026 | S | 2,501 | $16.2369 | D | 135,202 | D | |
| Class A Common StockF5 | holding | — | — | — | 10,110 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $1.01 | Jun 30, 2026 | M | 28,826 | D | — | Feb 24, 2030 | Class A Common Stock | 28,826 | 38,480 | D |
| Stock Option (right to buy)F6 | $1.01 | Jul 1, 2026 | M | 4,183 | D | — | Feb 24, 2030 | Class A Common Stock | 4,183 | 34,297 | D |
Explanation of responses
- F1These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5Includes 6,537 shares of the Issuer's Class A Common Stock acquired by the Reporting Person's spouse in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- F6The stock options are fully vested and exercisable.